| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 1.7K | 2.7% |
| Total Income | 1.7K | 2.3% |
| Expenditure | 1.5K | 1.8% |
| PBT | 177.43 | 1.2% |
| Net Profit | 137.69 | 10.1% |
| OPM | 4.47% | 0.01pp |
| NPM | 8.07% | 1.08pp |
| EPS | 7.01 | 10.0% |
Alembic Pharmaceuticals Reports Q3 FY2024-25 Financial Results: Net Sales up 4%, EBITDA at 16% of Sales, Net Profit at Rs.138 Crores
03 Feb 2025 · 3 Feb 2025, 08:10 pm
Summary
Alembic Pharmaceuticals Limited has reported its consolidated financial results for the third quarter ended 31st December, 2024. The company's net sales increased by 4% to Rs.1693 Crores, EBITDA was up by 1% to Rs. 271 Crores, and net profit stood at Rs.138 Crores. The India Branded Business grew by 3% to Rs. 614 crores, while the Animal Health business grew by 22%. The US Generics grew by 10% to Rs. 521 Crores, and the Ex-US International Generics grew by 10% to Rs. 299 Crores. The company received 7 ANDA approvals during the quarter, bringing the cumulative total to 219. The API business stood at Rs. 259 Crores for the quarter.
Key Highlights
- 1
Net Sales increased by 4% to Rs.1693 Crores
- 2
EBITDA up 1% to Rs. 271 Crores
- 3
Net Profit at Rs.138 Crores
- 4
India Branded Business grew by 3% to Rs. 614 crores
- 5
US Generics grew by 10% to Rs. 521 Crores, and Ex-US International Generics grew by 10% to Rs. 299 Crores
- 6
Received 7 ANDA approvals during the quarter, bringing the cumulative total to 219
- 7
API business at Rs. 259 Crores for the quarter
Management Comments
Mr. Shaunak Amin
MD, Alembic Pharmaceuticals Limited
In the current quarter, we faced market headwinds in the acute segment. However, other key therapies in our specialty business continued to outpace the market growth. To strengthen field force efficiency, we have enhanced Automation and AI, to upscale execution. This Transition has partly impacted quarter growth. We are confident to show a robust growth trajectory going forward. The US Business posted significant volume growth and the Ex-US markets continued to expand steadily. API Business is still under significant pricing pressure.”
Informational and educational content only. Not investment advice.